Clinical trial Recruiting at 1 site Observational Ages 18 and up

Cost-helpful look at iliac branch endoprostheses in aorto-iliac aneurysm repairs

Official title: Evaluation Of Cost-Effectiveness Of Iliac Branch Endoprostheses: A Multi-Center, Retrospective-Prospective, Observational Study/ Eunet-Hta Core Model

Run by IRCCS San Raffaele · NCT07096388 · Data updated 2026-11-12

This observational study tests the cost-effectiveness of Iliac Branch Endoprostheses in adults who undergo open or endovascular repair for aorto-iliac aneurysm.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment300 (estimated)
SponsorIRCCS San Raffaele
Academic / other
Locations1 site (Miano, Italy)
StatusRecruiting
StartedApril 28, 2026
Main results expectedDecember 1, 2029
Study endsMarch 1, 2030
Registry record updatedSeptember 17, 2026
Trial IDNCT07096388 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with an aorto-iliac aneurysm who are treated with elective open repair or iliac branch endovascular repair at IRCCS San Raffaele Hospital.

Probably not a fit

Patients treated with hybrid approaches, other non-branched endovascular techniques, prior repairs, or urgent/emergent cases may not see applicable cost-effectiveness insights.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-center, ambispective observational study enrolling about 300 adults treated between 2018 and 2025. It includes roughly 200 patients with retrospective data and 100 with prospective data, reflecting real-world decisions rather than random assignments. Patients undergo either open surgical repair or endovascular repair using iliac branch endoprostheses, with follow-up aligned to standard clinical guidelines. The study analyzes outcomes and costs across current practice to understand economic value. Participation is voluntary, and treatment allocation follows usual care rather than randomization.

Why it matters

Potential benefit: If successful, findings could clarify the economic value of iliac branch endoprostheses in aorto-iliac aneurysm repair and inform decision-making for clinicians and payers.

How similar studies have gone: Prior research on endovascular devices and cost-effectiveness in vascular surgery has shown mixed results; this study adds real-world economic data in a branded iliac branch context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients affected by an aorto-iliac aneurysm who received an elective open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft) or endovascular repair (with Iliac Branch Endoprosthesis)
* Adult patients ≥18 years
* Patients able to understand and sign the informed consent approved by the Ethics Committee of San Raffaele Hospital

Exclusion Criteria:

* Patients treated with a hybrid approach (concomitant open surgical and endovascular treatment)
* Patients treated with other endovascular techniques besides branched technology (e.g., physician-modified endografts, parallel grafts)
* Patients already submitted to prior open or endovascular repair for aorto-iliac aneurysm/prior aorto iliac aneurysm sac embolization
* Patients treated in urgent/emergent setting

Where it's running

  • IRCCS San Raffaele Hospital
    Miano, Italy, Italy
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.